Clinical Trial Update: Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) [Phase 3]

View source ↗

Summary

A Phase 3 study of ruxolitinib in pancreatic cancer was terminated; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Pancreatic Cancer | Phase 3 | Status: TERMINATED | Results posted: 2017-07-11